Navigation Links
Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
Date:2/28/2013

SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Cowen & Co. Annual Health Care Conference in Boston. The presentation is scheduled for Monday, March 4, 2013 at 3:30 p.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

WCG(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
3. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
4. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
5. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
8. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
9. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
10. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
11. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Research and Markets has ... Ischemic Stroke Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Ischemic Stroke epidemiology, Acute Ischemic ...
(Date:5/4/2016)... 2016 Research and ... Actinic Keratosis Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Landscape Highlights 2016, provides comprehensive insights into ... Actinic Keratosis market valuations and forecast, Actinic ...
(Date:5/3/2016)... 2016 Global Insulin Needles ... 09 key companies and supported with 272 tables ... study on the current state of the Insulin ... industry including definitions, classifications, applications and industry chain ... for the international market including development history, competitive ...
Breaking Medicine Technology:
(Date:5/5/2016)... Utah (PRWEB) , ... May 05, 2016 , ... ... life support certifications, is pleased to announce its new referral program, giving participants ... , “Healthcare is a tight-knit community, and we know many professionals share resources ...
(Date:5/5/2016)... ... May 05, 2016 , ... MAP Health ... announced today that Enlightened Solutions has joined the Premier Outcomes-Driven Provider Network. By ... continuum for their patients being treated for substance use. , Enlightened Solutions was ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Linfield College Online ... BSN degree program by waiving the $50 application fee for all qualified applicants from ... Nurses Week Fee Waiver option when applying . , With the ...
(Date:5/5/2016)... ... , ... Augusta Public Schools has teamed with CareDox to provide confidential and ... offices to streamline and bolster care for district students. , Augusta School District, ... schools serve 2,300 students among its six schools. , Monica Guilliams, BSN, RN, ...
(Date:5/5/2016)... ... May 05, 2016 , ... BloodHub, the nation’s ... service orders. Blood suppliers and their hospitals use BloodHub for order management, ... active users across 2,100 hospitals who use our platform to processes thousands of ...
Breaking Medicine News(10 mins):